Evommune Inc
EVMN
105 hedge funds and large institutions have $463M invested in Evommune Inc in 2026 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 36 increasing their positions, 13 reducing their positions, and 17 closing their positions.
177% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 13
141% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 17
25% more funds holding
Funds holding: 84 → 105 (+21)
0.03% more ownership
Funds ownership: 96% → 96.02% (+0.03%)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
29% less call options, than puts
Call options by funds: $5.91M | Put options by funds: $8.32M
42% less capital invested
Capital invested by funds: $793M → $463M (-$331M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.5M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$23.2M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.1M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$10.6M |
| 5 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$9.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$33.5M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$20.2M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$14.4M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$13.5M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$11.8M |
EVMN Hedge Fund Activity: Q2 2026 in Review
105 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Evommune Inc (EVMN) for Q2 2026, worth a combined $463M — down 42% from $793M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new EVMN positions and 17 closed out — a net gain of 24 holders — while 36 added to existing stakes and 13 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $32.5M. The largest seller was MPM BioImpact, exiting entirely with an estimated $33.5M sold.
- 105 institutional investors held Evommune Inc (EVMN) as of Q2 2026, up from 84 in Q1 2026.
- Funds reported $463M of Evommune Inc stock for Q2 2026, down 42% quarter-over-quarter.
- 41 funds opened new Evommune Inc positions in Q2 2026 and 17 closed out, a net change of +24 holders.
- The largest Evommune Inc buyer in Q2 2026 was Point72 Asset Management, an estimated $32.5M added.
- The largest Evommune Inc seller in Q2 2026 was MPM BioImpact, an estimated $33.5M sold.
Based on aggregated 13F filings for Q2 2026.